[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Moongkarndi P, Kaslungka S, Kosem N, Junnu S, Jongsomboonkusol S, Theptaranon Y, Neungton N: Cytotoxicity and apoptosis of ovarian and breast cancer cell lines induced by OVS1 monoclonal antibody and paclitaxel. Asian Pac J Allergy Immunol; 2003 Mar;21(1):31-41
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxicity and apoptosis of ovarian and breast cancer cell lines induced by OVS1 monoclonal antibody and paclitaxel.
  • OVS1 monoclonal antibody (MAb) produced against ovarian cancer is currently used to identify mucinous cystadenocarcinoma antigen as a tumor marker secreted in serum.
  • The potential of OVS1 MAb in ovarian cancer treatment was studied by evaluating the induction of cytotoxicity and apoptosis of SKOV3 ovarian cancer and BT549 breast cancer cell lines induced by OVS1.
  • Paclitaxel, an antitumor drug, was used as positive control and applied as a combined drug together with OVS1 MAb.
  • These findings on the induction of cytotoxicity and apoptosis by OVS1 MAb on cancer cell lines have implications on the potential application of OVS1 MAb for clinical therapy.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12931749.001).
  • [ISSN] 0125-877X
  • [Journal-full-title] Asian Pacific journal of allergy and immunology
  • [ISO-abbreviation] Asian Pac. J. Allergy Immunol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


2. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD: Fasting and cancer treatment in humans: A case series report. Aging (Albany NY); 2009 Dec;1(12):988-1007
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fasting and cancer treatment in humans: A case series report.
  • Short-term fasting (48 hours) was shown to be effective in protecting normal cells and mice but not cancer cells against high dose chemotherapy, termed Differential Stress Resistance (DSR), but the feasibility and effect of fasting in cancer patients undergoing chemotherapy is unknown.
  • Here we describe 10 cases in which patients diagnosed with a variety of malignancies had voluntarily fasted prior to (48-140 hours) and/or following (5-56 hours) chemotherapy.
  • None of these patients, who received an average of 4 cycles of various chemotherapy drugs in combination with fasting, reported significant side effects caused by the fasting itself other than hunger and lightheadedness.
  • Chemotherapy associated toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI).
  • The six patients who underwent chemotherapy with or without fasting reported a reduction in fatigue, weakness, and gastrointestinal side effects while fasting.
  • In those patients whose cancer progression could be assessed, fasting did not prevent the chemotherapy-induced reduction of tumor volume or tumor markers.
  • Although the 10 cases presented here suggest that fasting in combination with chemotherapy is feasible, safe, and has the potential to ameliorate side effects caused by chemotherapies, they are not meant to establish practice guidelines for patients undergoing chemotherapy.
  • Only controlled-randomized clinical trials will determine the effect of fasting on clinical outcomes including quality of life and therapeutic index.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fasting. Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Papillary / diet therapy. Cystadenocarcinoma, Serous / drug therapy. Esophageal Neoplasms / drug therapy. Female. Humans. Male. Middle Aged. Prostatic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cell Cycle. 2002 Nov-Dec;1(6):375-82 [12548008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6659-63 [15096581.001]
  • [Cites] J Pharmacol Exp Ther. 1980 Jun;213(3):551-6 [7193726.001]
  • [Cites] J Clin Invest. 1983 Feb;71(2):175-82 [6681614.001]
  • [Cites] J Nutr. 1986 Apr;116(4):641-54 [3958810.001]
  • [Cites] Cancer Res. 1988 Sep 1;48(17):4766-9 [2842038.001]
  • [Cites] Toxicol Lett. 1989 Mar;46(1-3):163-75 [2650023.001]
  • [Cites] Nutrition. 1989 May-Jun;5(3):155-71; discussion 172 [2520283.001]
  • [Cites] Endocr Rev. 1994 Feb;15(1):80-101 [8156941.001]
  • [Cites] Arch Dis Child. 1994 Nov;71(5):457-62 [7826122.001]
  • [Cites] Exp Gerontol. 1995 May-Aug;30(3-4):291-8 [7556508.001]
  • [Cites] Science. 2003 Feb 28;299(5611):1342-6 [12610293.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20915-24 [12665508.001]
  • [Cites] J Cell Biol. 1997 Jun 30;137(7):1581-8 [9199172.001]
  • [Cites] Mech Ageing Dev. 1998 Aug 14;104(2):149-58 [9792193.001]
  • [Cites] CA Cancer J Clin. 2006 Nov-Dec;56(6):323-53 [17135691.001]
  • [Cites] Free Radic Biol Med. 2007 Mar 1;42(5):665-74 [17291990.001]
  • [Cites] JAMA. 2007 Mar 7;297(9):986-94 [17341713.001]
  • [Cites] Annu Rev Nutr. 2007;27:193-217 [17428180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8215-20 [18378900.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4535-6 [18626003.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Nov;9(11):903-10 [18946478.001]
  • [Cites] Science. 2009 Jul 10;325(5937):201-4 [19590001.001]
  • [Cites] Int J Obes Relat Metab Disord. 2001 Aug;25(8):1233-9 [11477509.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2978-83 [12050283.001]
  • [Cites] Nature. 2003 Jan 9;421(6919):182-7 [12483226.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4301-5 [11389048.001]
  • (PMID = 20157582.001).
  • [ISSN] 1945-4589
  • [Journal-full-title] Aging
  • [ISO-abbreviation] Aging (Albany NY)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2815756
  • [Keywords] NOTNLM ; Cancer / Chemotherapy / IGF-I / Side-effect / Toxicity / fasting
  •  go-up   go-down


3. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP: Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res; 2002 May;8(5):1271-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we have tested the sensitivity of USPC cells to Herceptin treatment.
  • Fresh and established primary USPC cell lines were found to express significantly more HER-2/neu receptor by flow cytometry (on the average, 10-fold greater) when compared with HER-2/neu-positive primary or established breast and ovarian cancer cell lines (P < 0.001).
  • Importantly, although these USPC cell lines were resistant to chemotherapy in vivo and to natural killer- and complement-mediated cytotoxicity in vitro, they were found to be highly sensitive to Herceptin-mediated ADCC.
  • CONCLUSIONS: On the basis of these findings and previous reports showing a positive in vivo correlation between efficacy of Herceptin therapy and the level of HER-2/neu overexpression by tumor cells, we propose that Herceptin might be a novel and attractive therapeutic strategy in patients harboring chemotherapy-resistant, recurrent, or metastatic USPC.
  • [MeSH-major] Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Receptor, ErbB-2 / biosynthesis. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / pharmacology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Division / drug effects. Female. Flow Cytometry. Humans. Immunohistochemistry. Interleukin-2 / pharmacology. Killer Cells, Natural / immunology. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Rituximab. Trastuzumab. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / immunology. Tumor Cells, Cultured / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12006548.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Interleukin-2; 4F4X42SYQ6 / Rituximab; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


Advertisement
4. Stadlmann S, Gueth U, Wight E, Kunz-Schughart LA, Hartmann A, Singer G: Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma. J Clin Pathol; 2007 Mar;60(3):307-10
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Peroxisome proliferator-activated receptor gamma (PPARgamma) has emerged as a potential therapeutic target in several types of cancer.
  • METHODS: The immunoexpression of PPARgamma and its putative target cyclo-oxygenase 2 (COX2) was investigated in tumour tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas after conventional platinum-based chemotherapy.
  • CONCLUSIONS: The data indicate that PPARgamma may represent a potential target for second-line treatment in ovarian cancers.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Cystadenocarcinoma, Serous / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / metabolism. PPAR gamma / metabolism
  • [MeSH-minor] Adult. Aged. Drug Resistance, Neoplasm. Female. Humans. Immunoenzyme Techniques. Middle Aged. Protein Array Analysis / methods. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):28028-32 [10827178.001]
  • [Cites] Cancer Lett. 2006 May 8;236(1):133-41 [15979236.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1394-400 [11044367.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12):1640-7 [11401318.001]
  • [Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]
  • [Cites] Exp Cell Res. 2001 Jul 1;267(1):73-80 [11412039.001]
  • [Cites] Trends Mol Med. 2001 Sep;7(9):395-400 [11530334.001]
  • [Cites] Carcinogenesis. 2001 Sep;22(9):1379-83 [11532858.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Int J Oncol. 2002 Jun;20(6):1109-22 [12011987.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1205-11 [12181243.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4728-35 [12364466.001]
  • [Cites] Cancer J. 2002 Sep-Oct;8(5):395-9 [12416897.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):1-9 [12538445.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):597-602 [12594814.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jun;79(3):391-7 [12846423.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Dec;12(12):1925-37 [14640937.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):538-45 [14760075.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1181-9 [14871855.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):927-35 [14984962.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Feb;130(2):73-9 [14634802.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Oct 7;1:66 [14609433.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):633-8 [15266333.001]
  • [Cites] Cancer Treat Rev. 2004 Oct;30(6):545-54 [15325034.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 2004 Aug;39(8):529-32 [15363351.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 [9671760.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2783-840 [15517885.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):113-9 [15583697.001]
  • [Cites] FEBS Lett. 2005 Mar 14;579(7):1765-9 [15757673.001]
  • [Cites] Int J Gynecol Cancer. 2005 Mar-Apr;15(2):255-60 [15823108.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4769-74 [15930296.001]
  • [Cites] Expert Opin Investig Drugs. 2005 Jun;14(6):557-68 [16004588.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6300-10 [16144934.001]
  • [Cites] Methods Mol Med. 2005;114:257-68 [16156109.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5 [10984506.001]
  • (PMID = 16698954.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PPAR gamma; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC1860580
  •  go-up   go-down


5. Tagaya N, Kakihara Y, Hamada K, Sawada T, Kubota K: [Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer]. Gan To Kagaku Ryoho; 2004 Dec;31(13):2155-8
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer].
  • We evaluated the safety and efficacy of neoadjuvant chemotherapy with docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) in 5 patients with locally advanced breast cancer on an outpatient basis.
  • It was repeated 4 times every 3 weeks.
  • Breast conserving therapy was performed in two patients.
  • These findings suggested satisfactory effects of this neoadjuvant chemotherapy regimen.
  • This combination chemotherapy without severe adverse events would be an alternative choice of neoadjuvant chemotherapy on an outpatient basis.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Ambulatory Care. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Floxuridine / administration & dosage. Humans. Middle Aged. Preoperative Care. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15628762.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 039LU44I5M / Floxuridine; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


6. Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, Shih IeM: Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res; 2006 Feb 1;12(3 Pt 1):827-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Mesothelin is an emerging marker for cancer diagnosis and target-based therapy, yet relatively little is known about the clinical significance of mesothelin expression in tumors.
  • EXPERIMENTAL DESIGN: Mesothelin expression levels were compared among 81 publicly available serial analysis of gene expression (SAGE) libraries of various carcinoma and normal tissue types.
  • Immunohistochemistry staining scores were correlated with patient survival, tumor site, tumor grade, in vitro drug resistance, and differentiation status of tumor cells.
  • RESULTS: SAGE analysis showed that mesothelin was overexpressed in 50% of ovarian and pancreatic carcinomas but rarely in other cancer types, including liver, colon, kidney, prostate, and breast.
  • Based on Kaplan-Meier analysis, we found that a diffuse mesothelin staining (>50% of tumor cells) in primary high-grade ovarian carcinomas correlated significantly with prolonged survival in patients who had advanced-stage disease and had received optimal debulking surgery followed by chemotherapy (P = 0.023).
  • Mesothelin expression did not correlate significantly with patient age, tumor site, in vitro drug resistance, or tumor differentiation status (P > 0.10).
  • [MeSH-major] Cystadenocarcinoma, Serous / genetics. Gene Expression Regulation, Neoplastic. Membrane Glycoproteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Differentiation / drug effects. Drug Resistance, Neoplasm. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. In Vitro Techniques. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467095.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


7. Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD: Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer; 2010 Jul 02;10:349
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Development of innovative, effective therapies against recurrent/chemotherapy-resistant ovarian cancer remains a high priority.
  • METHODS: Because claudin-3 and -4 are the epithelial receptors for Clostridium perfringens enterotoxin (CPE), and are sufficient to mediate CPE binding, in this study we evaluated the in vitro and in vivo bioactivity of the carboxy-terminal fragment of CPE (i.e., CPE290-319 binding peptide) as a carrier for tumor imaging agents and intracellular delivery of therapeutic drugs.
  • Cell binding assays were used to assess the accuracy and specificity of the CPE peptide in vitro against primary chemotherapy-resistant ovarian carcinoma cell lines.
  • Confocal microscopy and biodistribution assays were performed to evaluate the localization and uptake of the FITC-conjugated CPE peptide in established tumor tissue.
  • RESULTS: Using a FITC-conjugated CPE peptide we show specific in vitro and in vivo binding to multiple primary chemotherapy resistant ovarian cancer cell lines.
  • Bio-distribution studies in SCID mice harboring clinically relevant animal models of chemotherapy resistant ovarian carcinoma showed higher uptake of the peptide in tumor cells than in normal organs.
  • Imunofluorescence was detectable within discrete accumulations (i.e., tumor spheroids) or even single chemotherapy resistant ovarian cancer cells floating in the ascites of xenografted animals while a time-dependent internalization of the FITC-conjugated CPE peptide was consistently noted in chemotherapy-resistant ovarian tumor cells by confocal microscopy.
  • CONCLUSIONS: Based on the high levels of claudin-3 and -4 expression in chemotherapy-resistant ovarian cancer and other highly aggressive human epithelial tumors including breast, prostate and pancreatic cancers, CPE peptide holds promise as a lead peptide for the development of new diagnostic tracers or alternative anticancer agents.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5007-11 [11016619.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6744-9 [11118061.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81 [11158614.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3869-76 [11358798.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):262-70 [11782386.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):8-16 [12468336.001]
  • [Cites] Mol Carcinog. 2003 Feb;36(2):53-9 [12557260.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Infect Immun. 1975 Aug;12(2):440-2 [168155.001]
  • [Cites] J Biol Chem. 1986 Feb 5;261(4):1801-7 [2418017.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):630-4 [7906395.001]
  • [Cites] Toxicon. 1996 Nov-Dec;34(11-12):1335-43 [9027990.001]
  • [Cites] J Cell Biol. 1997 Mar 24;136(6):1239-47 [9087440.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4334-42 [15899825.001]
  • [Cites] Virchows Arch. 2007 Sep;451(3):669-80 [17609977.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7977-82 [17804705.001]
  • [Cites] Am J Obstet Gynecol. 2009 Jul;201(1):70.e1-9 [19426958.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • (PMID = 20598131.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16359; United States / NCI NIH HHS / CA / R01 CA122728-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-3; 0 / Claudin-4; 0 / Cldn3 protein, mouse; 0 / Cldn4 protein, mouse; 0 / Enterotoxins; 0 / Membrane Proteins; 0 / Peptide Fragments; 0 / RNA, Messenger; 0 / enterotoxin, Clostridium
  • [Other-IDs] NLM/ PMC2908101
  •  go-up   go-down


8. Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, Leetanaporn R, Geater A: WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer; 2006;6:90
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have shown that WT1 plays an important role in the progression of disease and indicates a poorer prognosis of human malignancies such as acute myeloid leukemia and breast cancer.
  • During the study period, 163 patients were diagnosed with advanced serous epithelial ovarian carcinoma and had undergone complete post-operative chemotherapy, but the final study group comprised 99 patients.
  • The records of these women were reviewed and the paraffin-embedded tissue of these women stained with WT1 immunostaining.
  • For survival the HR of WT1 staining, adjusted for residual tumor and chemotherapy response, was 1.98 (95% CI 1.28-3.79), and for recurrence-free survival the HR was 3.36 (95% CI 1.60-7.03).
  • [MeSH-major] Cystadenocarcinoma, Serous / genetics. Gene Expression Regulation, Neoplastic. Genes, Wilms Tumor. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / genetics. WT1 Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Aug 1;90(3):1217-25 [9242555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8132-7 [9223327.001]
  • [Cites] Cancer Lett. 1997 Dec 23;121(2):169-75 [9570355.001]
  • [Cites] Jpn J Cancer Res. 1999 Feb;90(2):194-204 [10189890.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3B):2387-9 [10472362.001]
  • [Cites] J Obstet Gynaecol Res. 2005 Jun;31(3):268-76 [15916666.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):12-7 [16263157.001]
  • [Cites] Int J Gynecol Pathol. 2003 Apr;22(2):168-74 [12649672.001]
  • [Cites] Br J Haematol. 2003 Oct;123(1):49-59 [14510942.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):776-84 [14675314.001]
  • [Cites] FEBS Lett. 2004 Feb 27;560(1-3):183-91 [14988020.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):122-6 [15354736.001]
  • [Cites] Cancer. 1985 Dec 1;56(11):2727-32 [4052947.001]
  • [Cites] Nature. 1990 Jul 12;346(6280):194-7 [2164159.001]
  • [Cites] Mol Cell Biol. 1991 Mar;11(3):1707-12 [1671709.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1138-50 [1904477.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3071-9 [7949179.001]
  • [Cites] Genes Dev. 1995 Sep 1;9(17):2143-56 [7657166.001]
  • [Cites] EMBO J. 1996 Aug 15;15(16):4297-306 [8861958.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1995 Dec;63(2):115-24 [8903765.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):6945-56 [8943350.001]
  • [Cites] J Biol Chem. 1997 Jan 31;272(5):2901-13 [9006935.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2689-700 [9178767.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):369-72 [10684712.001]
  • [Cites] Int J Gynecol Pathol. 2000 Apr;19(2):158-63 [10782413.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4265-71 [11106242.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):246-52 [11488072.001]
  • [Cites] Gene. 2001 Aug 8;273(2):141-61 [11595161.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1167-71 [12006533.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):30678-87 [9388203.001]
  • (PMID = 16606472.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / WT1 Proteins
  • [Other-IDs] NLM/ PMC1479357
  •  go-up   go-down


9. Tanaka S, Kawamura T, Nakamura N, Teramoto K, Arii S: Mucinous cystadenocarcinoma of the pancreas developing during hormone replacement therapy. Dig Dis Sci; 2007 May;52(5):1326-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenocarcinoma of the pancreas developing during hormone replacement therapy.
  • Hormone replacement therapy (HRT) containing estrogens is generally used to relieve climacteric symptoms and to prevent osteoporosis and coronary heart disease [1], however, there has been increasing evidence of the HRT as the risk of hormone-dependent neoplasms including breast cancer [2], uterine endometrial cancer [3], ovarian cancer [4], and even lung cancer [5].
  • [MeSH-major] Cystadenocarcinoma, Mucinous / chemically induced. Estrogen Replacement Therapy / adverse effects. Neoplasms, Hormone-Dependent / chemically induced. Pancreatic Neoplasms / chemically induced. Stromal Cells / drug effects
  • [MeSH-minor] Female. Humans. Hysterectomy. Inhibins / analysis. Middle Aged. Pancreatectomy. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Splenectomy. Treatment Outcome. Ultrasonography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 1999 Feb;65(2):105-11 [9926740.001]
  • [Cites] Dig Dis Sci. 2006 Mar;51(3):629-32 [16614979.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):491-8 [16595785.001]
  • [Cites] Br J Surg. 1986 Jul;73(7):591 [3730799.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):59-63 [16314616.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):497-504 [11929950.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):281-91 [16557280.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):419-27 [12927427.001]
  • [Cites] Lancet. 2005 Apr 30-May 6;365(9470):1543-51 [15866308.001]
  • [Cites] JAMA. 2002 Aug 21;288(7):872-81 [12186605.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):897-909 [12459728.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • (PMID = 17372823.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 57285-09-3 / Inhibins
  •  go-up   go-down


10. Ozsaran AA, Dikmen Y, Terek MC, Ulukus M, Ozdemir N, Orgüc S, Erhan Y: Bilateral metastatic carcinoma of the breast from primary ovarian cancer. Arch Gynecol Obstet; 2000 Nov;264(3):166-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral metastatic carcinoma of the breast from primary ovarian cancer.
  • During the courses of chemotherapy; bilateral breast nodules, and bilateral axillary lymphadenopathies and a nodule in the vaginal cuff were identified.
  • The biopsy of both breasts, axillary lymph nodes and the nodule in the vaginal cuff revealed papillary serous cystadenocarcinoma.
  • Immunohistochemical staining of breast specimens were positive for ovarian tumor marker CA-125.
  • [MeSH-major] Breast Neoplasms / secondary. Cystadenocarcinoma / secondary. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Axilla. CA-125 Antigen / metabolism. Female. Humans. Lymphatic Metastasis. Pleural Effusion, Malignant. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / metabolism. Vaginal Neoplasms / secondary


11. Khalifeh I, Deavers MT, Cristofanilli M, Coleman RL, Malpica A, Gilcrease MZ: Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J; 2009 Mar-Apr;15(2):176-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal serous carcinoma presenting as inflammatory breast cancer.
  • Metastasis to the breast from extramammary malignancies is rare.
  • Nevertheless, its recognition is important because the prognosis and treatment differ from that of primary breast cancer.
  • We report a unique case of primary peritoneal serous carcinoma that initially presented as inflammatory breast cancer.
  • The patient received neoadjuvant chemotherapy for breast cancer and subsequently underwent bilateral total mastectomy and bilateral sentinel lymph node biopsy.
  • She was found to have extensive intralymphatic carcinoma in both breasts, with only focal minimal breast parenchymal involvement, and residual metastatic carcinoma in bilateral sentinel lymph nodes.
  • To our knowledge, this is the first reported case of an extramammary primary malignancy that not only presented as inflammatory breast cancer but also was diagnosed and initially treated as such.
  • [MeSH-major] Breast Neoplasms / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Diagnosis, Differential. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Inflammation / pathology. Magnetic Resonance Imaging. Mastectomy. Middle Aged. Neoplasm Metastasis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovariectomy. Sentinel Lymph Node Biopsy


12. Baslaim MM, Bakheet SM, Ezzat A, Al Suhaibani H, Tulbah A: 18-fluorodeoxyglucose positron emission tomography in cystic carcinoma of the breast. Breast J; 2002 Nov-Dec;8(6):371-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18-fluorodeoxyglucose positron emission tomography in cystic carcinoma of the breast.
  • Cystic infiltrating ductal carcinoma of the breast is uncommon and frequently misdiagnosed because of the predominant cystic presentation clinically.
  • Three premenopausal patients presented with huge cystic breast lesions measuring 10, 19, and 20 cm for 12-, 6-, 10-months duration, respectively.
  • In the first patient, mammography showed a high-density, well-circumscribed huge breast mass, whereas in the other two patients mammography was not possible because of the huge breast size.
  • In all three patients, breast ultrasound showed large cystic lesions suggestive of tumor with central necrosis or bleeding from which a variable amount (270, 1300, 600 ml) of bloody fluid was aspirated, respectively.
  • In all three patients, a whole-body positron emission tomography (PET) scan showed intense focal 18-fluorodeoxyglucose (FDG) breast uptake corresponding to the solid component and a ringlike uptake corresponding to the cystic component most likely representing tumor necrosis, hemorrhage, or both.
  • Furthermore, whole-body PET scan was valuable in predicting the response to chemotherapy, characterizing the pelviabdominal mass and detecting the presence of hepatic and spinal metastases in the three patients, respectively.
  • 18-FDG PET scan can help characterize a cystic breast mass by identifying the extent of the cystic and the solid component.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Carcinoma, Ductal, Breast / radionuclide imaging. Cystadenocarcinoma / radiography. Fluorodeoxyglucose F18. Tomography, Emission-Computed
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Neoplasm Staging / methods. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12390360.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Kayikçioğlu F, Boran N, Ayhan A, Güler N: Inflammatory breast metastases of ovarian cancer: a case report. Gynecol Oncol; 2001 Dec;83(3):613-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory breast metastases of ovarian cancer: a case report.
  • BACKGROUND: Metastasis to the breast from extramammary malignancies is rare.
  • CASE: A 35-year-old woman presented with bilaterally inflammatory breast involvement, 2 years after the diagnosis of stage IIIC epithelial ovarian cancer.
  • Neoplastic tissue was immunohistochemically positive using antibodies against OC125 and negative for gross cystic disease fluid protein-15 (BRST-2) and estrogen receptor in biopsy material in the breast.
  • Combination chemotherapy consisting of paclitaxel, cisplatin, and anthracycline was started.
  • She died 18 months after the breast metastasis.
  • The finding of isolated, distant metastases such as breast involvement without intraabdominal disease is extremely rare.
  • Determining the origin of the primary tumor is important in directing the actual therapy.
  • [MeSH-major] Breast Neoplasms / secondary. Cystadenocarcinoma, Papillary / secondary. Ovarian Neoplasms / pathology


14. Gingell D, Samuel A, Haynik D, McBee W, Kelley J, Zorn K, Bhargava R: Metastatic ovarian serous carcinoma presenting as inflammatory breast cancer: a case report. Int J Gynecol Pathol; 2010 May;29(3):243-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ovarian serous carcinoma presenting as inflammatory breast cancer: a case report.
  • A 42-year-old woman presented with localized irritation, erythema and sharp pain in the one breast.
  • After unsuccessful treatment for mastitis, an oncology consultation was obtained.
  • A breast biopsy revealed an invasive carcinoma and a diagnosis of inflammatory breast cancer was made.
  • The patient was treated with neo-adjuvant chemotherapy and subsequently underwent bilateral mastectomy.
  • A total abdominal hysterectomy and bilateral salpingo-oophorectomy was also performed at the same time due to the presence of a pelvic mass.
  • Morphologic and immunohistochemical examination of the specimens helped to clarify the correct diagnosis of primary ovarian carcinoma with widespread metastases to bilateral breasts.
  • [MeSH-major] Breast Neoplasms / secondary. Cystadenocarcinoma, Serous / secondary. Ovarian Neoplasms / pathology


15. Hoogendoorn WE, Hollema H, van Boven HH, Bergman E, de Leeuw-Mantel G, Platteel I, Fles R, Nederlof PM, Mourits MJ, van Leeuwen FE, Comprehensive Cancer Centers TAMARISK-group: Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat; 2008 Nov;112(1):99-108
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
  • We examined histopathologic and immunohistochemical characteristics of 332 patients with uterine corpus cancer following breast cancer, according to tamoxifen use.
  • Our results can be applied when weighing risks and benefits of tamoxifen versus other hormonal agents used in the prevention and treatment of breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Tamoxifen / therapeutic use. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / mortality. Aged. Cohort Studies. Cystadenocarcinoma, Serous / chemically induced. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / mortality. Endometrial Neoplasms / chemically induced. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / mortality. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / diagnosis. Prognosis. Retrospective Studies. Risk Factors. Sarcoma / chemically induced. Sarcoma / diagnosis. Sarcoma / mortality. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064567.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Investigator] Visser O; Damhuis RA; Louwman WJ; van Dijck JA; Westerman Y; Dirx MJ; Jansen-Landheer ML; de Munck L; Siesling S
  •  go-up   go-down


16. Nishimura N, Hachisuga T, Saito T, Kawarabayashi T: Subsequent endometrial carcinoma with adjuvant tamoxifen treatment in Japanese breast cancer patients. Int J Gynecol Cancer; 2001 Jul-Aug;11(4):272-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsequent endometrial carcinoma with adjuvant tamoxifen treatment in Japanese breast cancer patients.
  • This study aimed to detail the clinicopathologic features of endometrial carcinomas that developed in Japanese patients receiving adjuvant tamoxifen treatment for breast cancer patients.
  • Ten endometrial carcinomas in tamoxifen-treated breast cancer patients were collected from two medical centers.
  • The cell types comprised nine endometrioid adenocarcinomas and one serous carcinoma.
  • One patient developed a contralateral breast cancer during tamoxifen treatment.
  • No patient died of breast cancer.
  • We did not demonstrate a higher frequency of either high-grade tumors or unfavorable histologic subtypes in tamoxifen-treated Japanese breast cancer patients.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / etiology. Tamoxifen / adverse effects
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Aged. Asian Continental Ancestry Group. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / etiology. Cystadenocarcinoma, Serous / pathology. Female. Humans. Japan. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11520364.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


17. Amanti C, Lombardi A, Moscaroli A, Catracchia V, Lo Russo M, Marino G, Conte S, Provenza G: [Peritoneal papillary serous carcinoma in a patient with previous surgery for breast cancer: clinical case]. G Chir; 2006 Jan-Feb;27(1-2):45-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal papillary serous carcinoma in a patient with previous surgery for breast cancer: clinical case].
  • The cytoreductive surgery and the cisplatinum chemotherapy, and other treatments like immunotherapy and radiotherapy, increase the PSCP patient survival.
  • A case of a 51 years old patient with previous surgery for breast cancer is here described.
  • [MeSH-major] Breast Neoplasms / surgery. Cystadenocarcinoma, Papillary / surgery. Peritoneal Neoplasms / surgery

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608633.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


18. Cortesi L, De Matteis E, Rashid I, Cirilli C, Proietto M, Rivasi F, Federico M: Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study. Int J Gynecol Cancer; 2009 Nov;19(8):1358-63
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study.
  • INTRODUCTION: The aim of this study was to investigate the incidence of second primary tumors in patients with breast cancer (BC), with particular regard to bidirectional risk for endometrial cancer (EC).
  • RESULTS: A total of 499 women with primary BC developed a second tumor.
  • [MeSH-major] Breast Neoplasms / epidemiology. Endometrial Neoplasms / epidemiology. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Antineoplastic Agents, Hormonal / adverse effects. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / pathology. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / epidemiology. Cystadenocarcinoma, Serous / pathology. Female. Humans. Incidence. Italy / epidemiology. Middle Aged. Neoplasm Staging. Prognosis. Registries. Risk Factors. Survival Rate. Tamoxifen / adverse effects

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009890.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


19. Dallenbach-Hellweg G, Schmidt D, Hellberg P, Bourne T, Kreuzwieser E, Dören M, Rydh W, Rudenstam G, Granberg S: The endometrium in breast cancer patients on tamoxifen. Arch Gynecol Obstet; 2000 Apr;263(4):170-7
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The endometrium in breast cancer patients on tamoxifen.
  • We restudied histologically and immunohistochemically 17 endometrial carcinomas, 2 malignant mixed tumors and 180 endometria with benign changes during or after tamoxifen therapy.
  • None of 11 patients biopsied before starting tamoxifen therapy had advanced endometrial glandular proliferation in the second endometrial biopsy after tamoxifen treatment.
  • None of the 19 endometrial neoplasms after tamoxifen therapy was of the endometrioid type: 11 were mucinous adenocarcinomas, 4 clear cell carcinomas, 2 serous-papillary carcinomas, one carcinosarcoma and one malignant Mullerian mixed tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Endometrium / drug effects. Tamoxifen / adverse effects
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / ultrasonography. Adult. Aged. Aged, 80 and over. Biopsy. Carcinosarcoma / chemically induced. Carcinosarcoma / pathology. Carcinosarcoma / ultrasonography. Cystadenocarcinoma, Papillary / chemically induced. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / ultrasonography. Female. Humans. Immunohistochemistry. Middle Aged. Mixed Tumor, Mullerian / chemically induced. Mixed Tumor, Mullerian / pathology. Mixed Tumor, Mullerian / ultrasonography. Polyps. Retrospective Studies. Ultrasonography, Doppler, Color

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10834325.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


20. Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown JV 3rd: Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol; 2006 Feb;100(2):437-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
  • BACKGROUND: Paclitaxel is one of the most active agents in the treatment of ovarian carcinoma.
  • CASE: We present a case involving a 60-year-old ovarian cancer patient with a significant history of chemotherapy induced HSR.
  • She underwent optimal cytoreductive surgery and began adjuvant chemotherapy in 2000 until she suffered a severe HSR to paclitaxel.
  • In 2002, she was diagnosed with recurrent disease and underwent subsequent treatment with carboplatin, cisplatin, and doxorubicin, all of which resulted in severe HSR.
  • The patient began abraxane therapy in 2005 and has shown no signs of HSR.
  • CONCLUSION: Abraxane is a solvent free taxane, which can be administered without the pre-medications routinely used to prevent HSR.
  • Abraxane may offer paclitaxel HSR patients the benefit of continued taxane treatment.
  • Although the clinical activity of abraxane has not been extensively investigated in ovarian carcinoma, the distinct activity of paclitaxel and good results with recurrent metastatic breast cancer patients suggest additional evaluation with this drug is important.
  • [MeSH-major] Drug Hypersensitivity / etiology. Ovarian Neoplasms / drug therapy. Paclitaxel / adverse effects. Paclitaxel / therapeutic use
  • [MeSH-minor] Albumin-Bound Paclitaxel. Albumins / adverse effects. Albumins / therapeutic use. Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / surgery. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / surgery. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226797.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumin-Bound Paclitaxel; 0 / Albumins; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Ng JS, Han AC, Edelson MI, Rosenblum NG: Uterine papillary serous carcinoma presenting as distant lymph node metastasis. Gynecol Oncol; 2001 Mar;80(3):417-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One case was found incidentally at the time of axillary dissection for breast cancer and the second case in the workup of a neck mass.
  • Patients were treated with adjuvant chemotherapy.
  • This tumor should be considered in the differential diagnosis when patients present with metastatic high-grade papillary serous carcinomas and the primary site is unknown.
  • [MeSH-major] Cystadenocarcinoma, Papillary / pathology. Lymph Nodes / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Axilla. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neck

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11263944.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gleyze PO, Petit E, Doe A, Nguyen B, Poquet E, Colbert N: [Meningeal metastases of ovarian cancer. Contribution of imaging]. Presse Med; 2000 Mar 25;29(11):593-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most meningeal metastases occur in breast cancer, exceptionally in primary ovarian cancer.
  • The diagnosis was clinical, supported by cerebrospinal fluid analysis and computed tomography and magnetic resonance imaging.
  • DISCUSSION: Establishing the diagnosis of carcinomatous meningitis may be difficult.
  • If spinal tap is contraindicated or negative, imaging, particularly magnetic resonance imaging is highly contributive in establishing the diagnosis of secondary localization.
  • A precise evaluation of the invaded tissues is quite helpful in guiding therapeutic management based on chemotherapy, tumor resection or radiotherapy.
  • [MeSH-major] Cystadenocarcinoma, Papillary / diagnosis. Cystadenocarcinoma, Papillary / secondary. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Ovarian Neoplasms / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10776413.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Kolwijck E, Boss EA, van Altena AM, Beex LV, Massuger LF: Stage IV epithelial ovarian carcinoma in an 18 year old patient presenting with a Sister Mary Joseph's nodule and metastasis in both breasts: a case report and review of the literature. Gynecol Oncol; 2007 Dec;107(3):583-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: We describe an 18-year-old girl presenting with umbilical metastasis as a first sign of an extremely aggressive stage IV ovarian serous papillary adenocarcinoma without an objective response to chemotherapy and endocrine therapy.
  • She developed metastasis in both breasts and died 28 months after the initial diagnosis.
  • Furthermore, uncommon breast metastasis and a Sister Mary Joseph's nodule have never been described at such young age.
  • [MeSH-major] Breast Neoplasms / secondary. Ovarian Neoplasms / pathology. Umbilicus / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / secondary. Adolescent. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / secondary. Female. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17904207.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Hafezi-Bakhtiari S, Morava-Protzner I, Burnell MJ, Reardon E, Colgan TJ: Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment. J Obstet Gynaecol Can; 2010 Jul;32(7):698-702
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment.
  • Nevertheless, recognition of this mixed tumour is important for administration of appropriate chemotherapy.
  • CASE: A 65-year-old woman underwent resection of an ovarian mass after presenting with a pelvic mass and breast tenderness.
  • This pathologic diagnosis led to a specific chemotherapy regimen with cisplatin, etoposide, and bleomycin, suitable for both types of malignancy.
  • [MeSH-major] Choriocarcinoma / pathology. Cystadenocarcinoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20707961.001).
  • [ISSN] 1701-2163
  • [Journal-full-title] Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC
  • [ISO-abbreviation] J Obstet Gynaecol Can
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


25. Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, Lu KH: Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol; 2003 Dec;91(3):463-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age at the time of diagnosis was 68 years (range, 44-93 years).
  • A personal history of breast cancer was reported by 12.4% of the patients, and a family history of breast cancer was reported by 16%.
  • Among stage III patients, those who received chemotherapy had a longer OS than those who did not receive chemotherapy (P = 0.03).
  • CONCLUSION: In this population of nonselected patients with UPSC, approximately 20% had a personal or family history of breast cancer.
  • [MeSH-major] Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / surgery. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2003 Dec;91(3):461-2 [14675662.001]
  • (PMID = 14675663.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


26. Zhong Y, Sheng XG, Ma ZF, Ma YB, Liu NF, Chen YT, Gao R, Wang YY, Sun L: [Clinicopathological characteristics of hereditary ovarian cancer syndrome]. Zhonghua Fu Chan Ke Za Zhi; 2009 Sep;44(9):676-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean number of chemotherapy cycles received in two groups was 13.3 and 11.8 (P > 0.05).
  • CONCLUSION: Hereditary ovarian cancer mostly from maternal lineage are featuring in early age of onset, serous adenocarcinoma, advanced stage (stage III), and better prognosis after the comprehensive treated by cytoreductive surgery plus with chemotherapy.
  • [MeSH-major] Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Age of Onset. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / genetics. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Female. Genetic Diseases, Inborn / pathology. Genetic Diseases, Inborn / therapy. Genetic Predisposition to Disease. Humans. Middle Aged. Neoplasm Staging. Pedigree. Prognosis. Retrospective Studies. Risk Factors


27. Varras M, Akrivis Ch, Bellou A, Malamou-Mitsi VD, Antoniou N, Tolis C, Salamalekis E: Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up. Eur J Gynaecol Oncol; 2004;25(5):640-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up.
  • Preoperative diagnosis of fallopian tube carcinoma is difficult due to the rarity and silent course of this neoplasm.
  • FIGO stage was considered as IIIb and the patient received six courses of combined carboplatin-taxol chemotherapy.
  • At two years from onset of therapy the patient underwent a modified radical mastectomy and lymphadenectomy because of primary carcinoma of the right breast.
  • The patient was started on tamoxifen therapy, which she is still taking.
  • In conclusion, our study suggests an association between fallopian tube carcinoma and breast cancer and a good response of the patient to platinum-based chemotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Cystadenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Estrogen Antagonists / therapeutic use. Female. Humans. Mastectomy. Middle Aged. Neoplasm Staging. Postoperative Period. Preoperative Care. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493187.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


28. Atallah D, Checrallah A, Rouzier R, Ghossain MA, Chahine G: Retroperitoneal lymphangioleiomyoma mimicking ovarian tumor emerging after tamoxifen therapy. Obstet Gynecol; 2006 Sep;108(3 Pt 2):762-4
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymphangioleiomyoma mimicking ovarian tumor emerging after tamoxifen therapy.
  • CASE: A 44-year-old premenopausal woman with breast cancer treated with adjuvant tamoxifen presented with abdominal distension.
  • A thoraco-abdominopelvic enhanced computed tomography scan showed a 22 x 21 x 12 cm well-encapsulated, complex pelvic mass.
  • An ovarian cystadenocarcinoma was suspected.
  • We speculate that tamoxifen treatment may play a role in the development of this benign tumor.
  • [MeSH-major] Lymphangiomyoma / diagnosis. Ovarian Neoplasms. Retroperitoneal Neoplasms / diagnosis. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018494.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


29. Soslow RA, Slomovitz BM, Saqi A, Baergen RN, Caputo TA: Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences. Gynecol Oncol; 2000 Dec;79(3):430-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We further studied chemotherapeutic drug resistance by examining reports prepared using the Oncotech Extreme Drug Resistance Assay from 24 of the 50 study patients.
  • RESULTS: USC, OSC, and PSC patients were similar with respect to mean age at diagnosis, mean gravidity, mean parity, personal history of breast cancer, percentage treated with chemotherapy, and survival at 3 and 5 years postdiagnosis.
  • Significant clinical differences included a high prevalence of nulliparity in OSC (P = 0.05), a low prevalence of Caucasian race in USC (P = 0.008), a paucity of stage I patients in OSC and PSC (P = 0.03), a high prevalence of familial breast cancer in OSC (P = 0.06), and superior 2-year survival in OSC (P = 0.02).
  • USC, OSC, and PSCs patients did not demonstrate significant differences with respect to extreme drug resistance.
  • However, the following trends were noted (P = 0.06): more prevalent low drug resistance for cyclophosphamide in OSC compared with USC and more prevalent extreme drug resistance for etoposide in OSC compared with USC.
  • CONCLUSIONS: Therefore, despite significant clincial differences, the USCs and ESCs in our series do not differ significantly with respect to the expression of the tumor suppressor genes, cell surface adhesion molecules, and drug resistance proteins studied.
  • [MeSH-major] Cell Adhesion Molecules / biosynthesis. Cystadenocarcinoma, Serous / metabolism. Drug Resistance, Multiple. Genes, Tumor Suppressor. Mixed Tumor, Mullerian / metabolism. Nuclear Proteins. Ovarian Neoplasms / metabolism. Peritoneal Neoplasms / metabolism. Uterine Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Drug Resistance, Neoplasm. Female. Gene Expression. Glycoproteins / biosynthesis. Humans. Immunohistochemistry. Immunophenotyping. Middle Aged. P-Glycoproteins / biosynthesis. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-mdm2. Tumor Suppressor Protein p53 / biosynthesis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 11104615.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44v6 antigen; 0 / Cell Adhesion Molecules; 0 / Glycoproteins; 0 / Nuclear Proteins; 0 / P-Glycoproteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down






Advertisement